16627756Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Guilhot FBloodAntineoplastic Agents; Cytarabine; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; PyrimidinesAdult; Aged; Benzamides; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Retrospective Studies; Splenomegaly; Survival Analysis; Treatment Failure; Treatment OutcomeSurvival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006 Sep 01; 108(5):1478-84.Blood2006-04-20T00:00:002006Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000368Living Beings1341183530.294764AgedD000328Living Beings1578255770.254432AdultD000970Chemicals & Drugs40723510.435461Antineoplastic AgentsD001549Chemicals & Drugs942260.914065BenzamidesD003561Chemicals & Drugs512180.93221CytarabineD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedAuthorship 294263D013163Disorders16270.994518SplenomegalyD005260Physiology1992444050.191167FemaleD010879Chemicals & Drugs1102720.858215PiperazinesD006801Living Beings2262862810.130052HumansD016026Procedures962850.90886Bone Marrow TransplantationD008297Physiology1931408600.201617MaleMedicine-Hematology and Oncology0.07210090.07210091authors10.2522has subject areaD016896Concepts & Ideas101179490.402389Treatment OutcomeD016898Chemicals & Drugs832330.923677Interferon-alphaD018450Physiology49815310.700842Disease ProgressionD011743Chemicals & Drugs1373700.795259PyrimidinesD016019Concepts & Ideas43415360.742907Survival AnalysisD017211Concepts & Ideas1712840.927969Treatment FailureD017326Activities & BehaviorsProcedures741690.934989Clinical Trials, Phase III as TopicD000068877451260.961421Imatinib MesylateD012189Concepts & Ideas114884310.376516Retrospective StudiesD015464Disorders401730.886112Leukemia, Myelogenous, Chronic, BCR-ABL PositiveUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.Professortrue1ProfessorProfessor